By: Senator(s) Fillingane, Hill, McDaniel, To: Drug Policy; Judiciary, Jackson (11th), Jordan, Sojourner

Division B

SENATE BILL NO. 2119 (As Passed the Senate)

AN ACT TO AUTHORIZE PHARMACIES TO SELL AND PERSONS TO PURCHASE, WITHOUT A PRESCRIPTION, PRODUCTS THAT CONTAIN CERTAIN 3 QUANTITIES OF PSEUDOEPHEDRINE OR EPHEDRINE; TO REQUIRE PHARMACIES SELLING PRODUCTS AUTHORIZED UNDER THIS ACT TO USE THE NPLEX SYSTEM 5 BEFORE SELLING THOSE PRODUCTS; TO REQUIRE PHARMACIES TO MAINTAIN AN ELECTRONIC LOG OF REQUIRED INFORMATION FOR EACH TRANSACTION; TO 7 REQUIRE THE PURCHASER OF THE PACKAGE TO BE AT LEAST EIGHTEEN YEARS OF AGE, AS SHOWN BY VALID IDENTIFICATION, AND TO SIGN A RECORD OF 8 9 EACH TRANSACTION; TO PROVIDE CRIMINAL PENALTIES FOR VIOLATIONS OF 10 THIS ACT; TO AMEND SECTION 41-29-117, MISSISSIPPI CODE OF 1972, TO 11 CONFORM; AND FOR RELATED PURPOSES.

- 12 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MISSISSIPPI:
- under Section 73-21-105 to sell or distribute to a person, without 14

SECTION 1. (1) (a) It is lawful for a pharmacy registered

- 15 a prescription, products containing not more than three and six
- tenths (3.6) grams per day and not more than seven and two tenths 16
- (7.2) grams per thirty-day period of pseudoephedrine or ephedrine, 17
- 18 and it is lawful for a person to purchase products containing
- 19 those ingredients from a registered pharmacy without a
- 20 prescription.

13

- 21 (b) All products authorized under this subsection (1)
- 22 must be stored by a pharmacy by placing the products behind a

- 23 counter in an area within the pharmacy where the public is not
- 24 permitted.
- 25 (c) Any products authorized under this subsection (1)
- 26 sold by a pharmacy must be sold by an individual licensed as a
- 27 pharmacist or by an employee of the pharmacy under the direct
- 28 supervision and control of a licensed pharmacist.
- 29 (d) No pharmacy may sell or distribute, and no person
- 30 may purchase, more products than allowed under this section unless
- 31 by valid prescription. It is not a defense in a prosecution under
- 32 this section that no money was exchanged during a transaction that
- 33 would otherwise be unlawful under this section.
- 34 (2) A pharmacy selling products in a manner authorized under
- 35 subsection (1) of this section must:
- 36 (a) Use the National Precursor Log Exchange (NPLEX)
- 37 system administered by the National Association of Drug Diversion
- 38 Investigators, provided that the system is available to pharmacies
- 39 or retailers in the state without a charge for accessing the NPLEx
- 40 system, before completing the over-the-counter sale of each
- 41 product authorized under subsection (1) of this section. Before
- 42 completing a sale of an over-the-counter material, compound,
- 43 mixture, or preparation containing any detectable quantity of
- 44 pseudoephedrine or ephedrine, its salts or optical isomers, or
- 45 salts of optical isomers a pharmacy or retailer shall
- 46 electronically submit the information required under subsection
- 47 (b) of this subsection (2) to the NPLEx system. The pharmacy or

- 48 retailer shall not complete the sale if the NPLEx system generates
- 49 a stop-sale alert. The system shall contain an override function
- 50 that may be used by an agent of a retail establishment who is
- 51 dispensing the drug product, and who has a reasonable fear of
- 52 imminent bodily harm if the transaction is not completed. The
- 53 system shall create a record of each use of the override
- 54 mechanism.
- (b) Maintain an electronic log of required information
- 56 for each transaction, and require the purchaser of the package to
- 57 be at least eighteen (18) years of age and provide a valid,
- 58 unsuspended driver's license or nondriver identification card
- 59 issued by this state or another state, a United States Uniformed
- 60 Services Privilege and Identification Card, or a United States or
- 61 foreign passport, and to sign a written or electronic log
- 62 attesting to the validity of the information provided for each
- 63 transaction. The record of each transaction must include the
- 64 information from the identification card as well as the type of
- 65 and government entity issuing the identification card used, the
- 66 name, date of birth, and current address of the purchaser, the
- 67 date and time of the sale, the name of the compound, mixture, or
- 68 preparation being sold, and the total amount, in grams or
- 69 milligrams, of pseudoephedrine or ephedrine being sold.
- 70 (c) Maintain a written log or an alternative electronic
- 71 recordkeeping mechanism if a pharmacy or retailer experiences
- 72 mechanical or electronic failure of the required electronic

- 73 tracking system until such time as the pharmacy or retailer is
- 74 able to comply with the electronic sales-tracking requirement. No
- 75 person shall purchase, receive or otherwise acquire more than
- 76 three and six-tenths (3.6) grams per day or seven and two-tenths
- 77 (7.2) grams of pseudoephedrine or ephedrine within any thirty-day
- 78 period.
- 79 (3) The National Association of Drug Diversion
- 80 Investigators shall provide real-time access to the NPLEx
- 81 information through the NPLEx online portal to law enforcement in
- 82 the state.
- 83 (4) (a) Pseudoephedrine and ephedrine products dispensed
- 84 pursuant to a legitimate prescription are exempt from this
- 85 section.
- 86 (b) The amounts of pseudoephedrine and ephedrine
- 87 products dispensed to a person pursuant to a legitimate
- 88 prescription shall not be considered under subsection (1)(a) of
- 89 this section.
- 90 (5) A violation of this section is a misdemeanor and is
- 91 punishable as follows:
- 92 (a) For a first offense, by a fine not to exceed One
- 93 Thousand Dollars (\$1,000.00).
- 94 (b) For a second or subsequent offense, by a fine not
- 95 to exceed Ten Thousand Dollars (\$10,000.00).
- 96 (6) A pharmacist who is the general owner or operator of an
- 97 establishment where pseudoephedrine and ephedrine products are

| 98 available for sale shall not be penalized under this se | avallable | not be benalized under this s | section i | _ () L |
|--|-----------|-------------------------------|-----------|--------|
|--|-----------|-------------------------------|-----------|--------|

- 99 the conduct of an employee if the retailer documents that an
- 100 employee training program approved by the Mississippi Board of
- 101 Pharmacy was conducted by the pharmacist. The Mississippi Board
- 102 of Pharmacy shall develop or approve all training programs for
- 103 pharmacy employees.
- 104 (7) A person who resides in a state that requires a
- 105 prescription for the purchase of pseudoephedrine or ephedrine, or
- 106 who presents identification from a state that requires a
- 107 prescription for the purchase of pseudoephedrine or ephedrine, may
- 108 purchase those products only upon presentation of a valid
- 109 prescription for the pseudoephedrine or ephedrine.
- 110 (8) This section shall stand repealed on January 1, 2024.
- 111 **SECTION 2.** Section 41-29-117, Mississippi Code of 1972, is
- 112 amended as follows:
- 113 41-29-117. (A) The controlled substances listed in this
- 114 section are included in Schedule III.
- 115 SCHEDULE III
- 116 (a) **Stimulants**. Any material, compound, mixture, or
- 117 preparation which contains any quantity of the following
- 118 substances or their salts, isomers, or salts of isomers, of the
- 119 following substances:
- 120 (1) Benzphetamine;
- 121 (2) Chlorphentermine;
- 122 (3) Clortermine;

| 123 | (4) Phendimetrazine. |
|-----|--|
| 124 | (b) Depressants. Unless listed in another schedule, |
| 125 | any material, compound, mixture, or preparation which contains any |
| 126 | quantity of the following substances: |
| 127 | (1) Any substance which contains any quantity of a |
| 128 | derivative of barbituric acid, or any salt of a derivative of |
| 129 | barbituric acid, except those substances which are specifically |
| 130 | listed in other schedules; |
| 131 | (2) Unless specifically excepted or unless listed |
| 132 | in another schedule, any compound, mixture or preparation |
| 133 | containing any of the following substances or any salt of the |
| 134 | substances specifically included in this subsection (2) and one or |
| 135 | more other active medicinal ingredients which are not listed in |
| 136 | any other schedule: |
| 137 | (i) Amobarbital; |
| 138 | (ii) Secobarbital; |
| 139 | (iii) Pentobarbital; |
| 140 | (3) Any suppository dosage form containing any of |
| 141 | the following substances or any salt of any of the substances |
| 142 | specifically included in this subsection (3) approved by the Food |
| 143 | and Drug Administration for marketing only as a suppository: |
| 144 | (i) Amobarbital; |
| 145 | (ii) Secobarbital; |
| 146 | (iii) Pentobarbital; |
| 147 | (4) Chlorhexadol; |

```
148
                     (5)
                         Embutramide;
149
                         Any drug product containing
                     (6)
     gamma-hydroxybutyric acid, including its salts, isomers and salts
150
     of isomers, for which an application is approved under Section 505
151
152
     of the Federal Food, Drug and Cosmetic Act;
153
                     (7)
                         Ketamine; its salts, isomers, and salts of
154
     isomers; other names include
155
     (+)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone;
156
                         Lysergic acid;
                     (8)
157
                     (9)
                         Lysergic acid amide;
158
                     (10) Methyprylon;
159
                           Perampanel; its salts, isomers, and salts of
                     (11)
160
     isomers;
161
                     (12)
                           Sulfondiethylmethane;
162
                     (13)
                           Sulfonethylmethane;
163
                     (14)
                           Sulfonmethane;
164
                           Tiletamine and zolazepam or any salt thereof;
                     (15)
     other names for the tiletamine and zolazepam combination product
165
166
     include: telazol; other names for tiletamine include:
167
     2-(ethylamino)-2-(2-thienyl)-cyclohexanone; other names for
168
     zolazepam include: 4-(2-fluorophenyl)-6,8-dihydro 1,3,
169
     8-trimethylpyrazolo-[3,4-e](1,4)-diazepin-7(1H)-one, flupyrazapon.
170
                (C)
                    Nalorphine.
171
                     Any material, compound, mixture or preparation
                (d)
     which contains any quantity of ephedrine or pseudoephedrine,
172
```

| 173 | except. | for | anv | product. | t.hat. | contains | anv | quantity | of |
|---------------------|---------|----------------------------------|---------------|----------|--------|-----------|---------------|-----------|---------|
| 1 / 0 | CZICCPC | $_{\rm T}$ $_{\rm C}$ $_{\rm T}$ | α_{11} | produce | CIICC | COLLCATIO | α_{11} | quarrerey | \circ |

- 174 pseudoephedrine or ephedrine that is sold subject to the quantity
- 175 restrictions authorized in Section 1 of this act.
- 176 (e) Narcotic drugs. Any material, compound, mixture,
- 177 or preparation containing limited quantities of any of the
- 178 following narcotic drugs, or any salts thereof:
- 179 (1) Not more than one and eight-tenths (1.8) grams
- 180 of codeine, or any of its salts, per one hundred (100) milliliters
- 181 or not more than ninety (90) milligrams per dosage unit, with an
- 182 equal or greater quantity of an isoquinoline alkaloid of opium;
- 183 (2) Not more than one and eight-tenths (1.8) grams
- 184 of codeine, or any of its salts, per one hundred (100) milliliters
- 185 or not more than ninety (90) milligrams per dosage unit, with one
- 186 or more active, nonnarcotic ingredients in recognized therapeutic
- 187 amounts;
- 188 (3) Not more than one and eight-tenths (1.8) grams
- 189 of dihydrocodeine, or any of its salts, per one hundred (100)
- 190 milliliters or not more than ninety (90) milligrams per dosage
- 191 unit, with one or more active, nonnarcotic ingredients in
- 192 recognized therapeutic amounts;
- 193 (4) Not more than three hundred (300) milligrams
- 194 of ethylmorphine, or any of its salts, per one hundred (100)
- 195 milliliters or not more than fifteen (15) milligrams per dosage
- 196 unit, with one or more active, nonnarcotic ingredients in
- 197 recognized therapeutic amounts;

| 198 | (5) Not more than five hundred (500) milligrams of |
|-----|--|
| 199 | opium per one hundred (100) milliliters or per one hundred (100) |
| 200 | grams, or not more than twenty-five (25) milligrams per dosage |
| 201 | unit, with one or more active, nonnarcotic ingredients in |
| 202 | recognized therapeutic amounts; |
| 203 | (6) Not more than fifty (50) milligrams of |
| 204 | morphine, or any of its salts, per one hundred (100) milliliters |
| 205 | or per one hundred (100) grams with one or more active, |
| 206 | nonnarcotic ingredients in recognized therapeutic amounts. |
| 207 | (f) Anabolic steroids. Unless specifically exempted or |
| 208 | listed in another schedule, any material, compound, mixture or |
| 209 | preparation containing any quantity of any of the following |
| 210 | anabolic steroids (any drug or hormonal substance chemically and |
| 211 | pharmacologically related to testosterone other than estrogens, |
| 212 | progestins, corticosteroids and dehydroepiandrosterone): |
| 213 | (1) 3beta, 17-dihydroxy-5a-androstane; |
| 214 | (2) 3alpha,17beta-dihydroxy-5a-androstane; |
| 215 | (3) 5alpha-androstan-3,17-dione; |
| 216 | (4) 1-androstenediol |
| 217 | (3beta,17beta-dihydroxy-5alpha-androst-1-ene); |
| 218 | (5) 1-androstenediol |
| 219 | (3alpha,17beta-dihydroxy-5alpha-androst-1-ene); |
| 220 | (6) 4-androstenediol |
| 221 | (3beta, 17beta-dihydroxy-androst-4-ene); |

```
222
                     (7)
                          5-androstenediol
223
     (3beta, 17beta-dihydroxy-androst-5-ene);
224
                     (8)
                          1-androstenedione ([5alpha]-androst-1-en-3,
225
     17-dione);
226
                     (9)
                         4-androstenedione (androst-4-en-3,17-dione);
227
                     (10) 5-androstenedione (androst-5-en-3,17-dione);
228
                     (11) Bolasterone
229
     (7alpha, 17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one);
230
                     (12)
                          Boldenone
231
     (17beta-hydroxyandrost-1, 4, -diene-3-one);
232
                     (13)
                           Boldione (androsta-1, 4-diene-3, 17-dione);
233
                     (14) Calusterone
234
     (7beta, 17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one);
235
                     (15) Clostebol
     (4-chloro-17beta-hydroxyandrost-4-en-3-one);
236
237
                     (16)
                           Dehydrochloromethyltestosterone
238
     (4-chloro-17beta-hydroxy-17alpha-methylandrost-1,4-dien-3-one);
239
                     (17) Desoxymethyltestosterone
240
     (17alpha-methyl-5alpha-androst-2-en-17beta-ol, also known as
241
     madol);
242
                     (18)
                           Delta1-dihydrotestosterone (also known as
243
     1-testosterone) (17beta-hydroxy-5alpha-androst-1-en-3-one);
244
                     (19)
                           4-dihydrotestosterone
245
     (17beta-hydroxy-androstan-3-one);
```

```
246
                     (20)
                           Drostanolone
247
     (17beta-hydroxy-2alpha-methyl-5alpha-androstan-3-one);
248
                     (21) Ethylestrenol
249
     (17alpha-ethyl-17beta-hydroxyestr-4-ene);
250
                     (22)
                         Fluoxymesterone
251
     (9-fluoro-17alpha-methyl-11beta,
252
     17beta-dihydroxyandrost-4-en-3-one);
253
                     (23)
                           Formebolone
254
     (2-formyl-17alpha-methyl-11alpha, 17beta-dihydroxyandrost-1,
255
     4-dien-3-one);
256
                     (24)
                          Furazabol
257
     (17alpha-methyl-17beta-hydroxyandrostano[2,3-c]-furazan);
258
                     (25) 13beta-ethyl-17alpha-hydroxygon-4-en-3-one;
259
                           4-hydroxytestosterone
                     (26)
     (4,17beta-dihydroxyandrost-4-en-3-one);
260
261
                     (27)
                           4-hydroxy-19-nortestosterone
262
     (4,17beta-dihydroxy-estr-4-en-3-one);
263
                     (28) Mestanolone
264
     (17alpha-methyl-17beta-hydroxy-5-androstan-3-one);
265
                     (29) Mesterolone
266
     (1alpha-methyl-17beta-hydroxy-[5alpha]-androstan-3-one);
267
                     (30) Methandienone
268
     (17alpha-methyl-17beta-hydroxyandrost-1, 4-dien-3-one);
269
                     (31)
                          Methandriol (17alpha-methyl-3beta,
270
     17beta-dihydroxyandrost-5-ene);
                       S. B. No. 2119
                                               ~ OFFICIAL ~
     21/SS08/R284PS
```

PAGE 11

```
271
                     (32)
                           Methasterone (2[alpha],
272
     17[alpha]-dimethyl-5[alpha]-androstan-17[beta]-ol-3-one;
273
                     (33)
                         Methenolone
274
     (1-methyl-17beta-hydroxy-5alpha-androst-1-en-3-one);
275
                     (34)
                           17alpha-methyl-3beta,
276
     17beta-dihydroxy-5a-androstane;
277
                           17alpha-methyl-3alpha,
                     (35)
278
     17beta-dihydroxy-5a-androstane;
279
                     (36)
                           17alpha-methyl-3beta,
280
     17beta-dihydroxyandrost-4-ene;
281
                     (37)
                           17alpha-methyl-4-hydroxynandrolone
282
     (17alpha-methyl-4-hydroxy-17beta-hydroxyestr-4-en-3-one);
283
                     (38) Methyldienolone
284
     (17alpha-methyl-17beta-hydroxyestra-4,9(10)-dien-3-one);
285
                     (39)
                           Methyltrienolone
     (17alpha-methyl-17beta-hydroxyestra-4,9-11-trien-3-one);
286
287
                     (40)
                          Methyltestosterone
288
     (17alpha-methyl-17beta-hydroxyandrost-4-en-3-one);
289
                     (41)
                          Mibolerone
290
     (7alpha, 17alpha-dimethyl-17beta-hydroxyestr-4-en-3-one);
291
                     (42) 17alpha-methyl-Deltal-dihydrotestosterone (17b
292
     beta-hydroxy-17alpha-methyl-5alpha-androst-1-en-3-one) (also known
     as 17-alpha-methyl-1-testosterone);
293
294
                     (43) Nandrolone (17beta-hydroxyestr-4-en-3-one);
```

```
295
                     (44)
                          19-nor-4-androstenediol
296
     (3beta, 17beta-dihydroxyestr-4-ene);
297
                     (45) 19-nor-4-androstenediol
298
     (3a, 17beta-dihydroxyestr-4-ene);
299
                     (46) 19-nor-5-androstenediol
300
     (3beta, 17beta-dihydroxyestr-5-ene);
301
                     (47) 19-nor-5-androstenediol
302
     (3alpha, 17beta-dihydroxyestr-5-ene);
303
                     (48)
                         19-nor-4,9(10)-androstadienedione
304
     (estra-4, 9(10) -diene3, 17-dione,
305
     19-norandrosta-4,9(10)-diene-3,17-dione);
306
                     (49) 19-nor-4-androstenedione
307
     (estr-4-en-3,17-dione);
308
                     (50) 19-nor-5-androstenedione
309
     (estr-5-en-3,17-dione);
310
                     (51) Norbolethone
311
     (13beta, 17alpha-diethyl-17beta-hydroxygon-4-en-3-one);
312
                     (52) Norclostebol
313
     (4-chloro-17beta-hydroxyestr-4-en-3-one);
314
                     (53) Norethandrolone
315
     (17alpha-ethyl-17beta-hydroxyestr-4-en-3-one);
316
                     (54) Normethandrolone
317
     (17alpha-methyl-17beta-hydroxyestr-4-en-3-one);
318
                     (55) Oxandrolone
     (17alpha-methyl-17beta-hydroxy-2-oxa-[5alpha]-androstan-3-one);
319
                       S. B. No. 2119
                                               ~ OFFICIAL ~
```

21/SS08/R284PS

PAGE 13

```
320
                     (56)
                           Oxymesterone
321
     (17alpha-methyl-4,17beta-dihydroxyandrost-4-en-3-one);
322
                     (57) Oxymetholone
323
     (17alpha-methyl-2-hydroxymethylene-17beta-hydroxy-[5alpha]-
324
     androstan-3-one);
325
                     (58) Prostanozol
326
     (17[beta]-hydroxy-5[alpha]-androstano[3,2-c]pyrazole)
327
                     (59)
                           Stanozolol
328
     (17alpha-methyl-17beta-hydroxy-[5alpha]-androst-2-eno[3,2-c]-
329
     pyrazole);
330
                           Stenbolone
                     (60)
331
     (17beta-hydroxy-2-methyl-[5alpha]-androst-1-en-3-one);
332
                     (61) Testolactone
333
     (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid
334
     lactone);
335
                     (62)
                           Testosterone
336
     (17beta-hydroxyandrost-4-en-3-one);
337
                          Tetrahydrogestrinone
                     (63)
338
     (13beta, 17alpha-diethyl-17beta-hydroxygon-4, 9, 11-trien-3-one);
339
                     (64) Trenbolone
340
     (17beta-hydroxyestr-4,9,11-trien-3-one);
341
                     (65) Any salt, ester, or ether of a drug or
342
     substance described in this paragraph. Except such term does not
343
     include an anabolic steroid that is expressly intended for
     administration through implants to cattle or other nonhuman
344
```

| 345 | species and that has been approved by the Secretary of Health and |
|-----|---|
| 346 | Human Services for such administration. If any person prescribes, |
| 347 | dispenses, or distributes such steroid for human use, the person |
| 348 | shall be considered to have prescribed, dispensed or distributed |
| 349 | an anabolic steroid within the meaning of this paragraph. |

- 350 (g) Any material, compound, mixture or preparation 351 which contains any quantity of buprenorphine or its salts.
- 352 (h) Dronabinol (synthetic) in sesame oil and
 353 encapsulated in a soft gelatin capsule in a United States Food and
 354 Drug Administration approved drug product.
- 355 (B) Any material, compound, mixture or preparation which
 356 contains any quantity of a Schedule III controlled substance other
 357 than butalbital, and is listed as an exempt substance in 21 CFR,
 358 Section 1308.22, 1308.24, 1308.26, 1308.32 or 1308.34, shall be
 359 exempted from the provisions of the Uniform Controlled Substances
 360 Law.
- 361 **SECTION 3.** This act shall take effect and be in force from 362 and after January 1, 2022.